Friday, GSK plc (NYSE:GSK) released the headline results of the MATINEE Phase 3 trial evaluating Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5) in adults with chronic obstructive pulmonary disease (COPD), or smoker’s lungs.
The trial recruited COPD patients with broad clinical presentations of chronic bronchitis and/or emphysema who were receiving optimized inhaled maintenance therapy.
Also Read: Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population.
Participants were also required to have evidence of type 2 inflammation characterized by raised blood eosinophil count.
MATINEE met its primary endpoint with the ...